As women live longer and speak more openly about the full texture of midlife, some are turning to testosterone — long cast as a male hormone — to reclaim a vitality that estrogen therapy alone does not always restore. In the quiet aftermath of menopause, where desire and energy can quietly recede, a modest hormonal adjustment is prompting both personal reckonings and medical reexamination. The science is still catching up to the need, but the conversation itself marks a shift in how medicine listens to women's bodies.
Women Turn to Testosterone Therapy to Ease Menopause Symptoms
Cobertura Relacionada
An NBC Los Angeles news helicopter crashed in Chatsworth on Tuesday evening, killing at least three people with two othe…
BBC News · Sep 16 LA news helicopter crashes while covering bus collision; 3 deadAn NBC Los Angeles news helicopter crashed in Chatsworth while covering a deadly bus collision, killing three people abo…
The Canberra Times · Sep 16 Three killed in helicopter crash near Los AngelesAt least three people died when a helicopter crashed in Chatsworth, suburban Los Angeles, near where emergency crews wer…
Inside Precision Medicine · Sep 16 AACR Report: FDA Approves 10 Targeted Cancer Therapies in 12 MonthsThe 2026 AACR Cancer Progress Report documents FDA approval of 10 new molecularly targeted cancer therapies and companio…
Sesgo y Encuadre
No hay datos de análisis detallado para esta lente. Intenta volver a ejecutar las lentes desde el panel de administración.
Impacto Geopolítico
This article discusses medical treatment options for menopause symptoms and has no geopolitical implications.
Lente Económico
Growing adoption of testosterone therapy for menopause symptom management expands pharmaceutical market opportunities and shifts treatment paradigms in women's healthcare.
Women gain expanded treatment options for menopause symptoms, potentially improving quality of life and productivity. However, increased healthcare costs may result from new prescriptions, and insurance coverage variability could create access disparities.
Regulatory bodies (FDA) may need to clarify approval pathways and labeling for off-label testosterone use in women. Insurance companies will likely develop coverage policies. Medical societies may issue updated clinical guidelines. Potential scrutiny regarding long-term safety data and equitable access.